Tag Archives: BIO CEO & Investor Conference

BIO CEO 2012 Opening Remarks

The 14th Annual BIO CEO & Investor Conference started with a busy turnout Monday at the Waldorf=Astoria Hotel in New York City. Meetings scheduled between institutional investors and biotech executives hit a record high and the opening plenary was a standing room only event. Kicking off the plenary were opening remarks from BIO’s Executive Vice President of Emerging Companies and Business Development, Alan Eisenberg. A copy of the slides can be found here: Opening Plenary Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Value Drivers Under the Influence – How Licensing and Key Events Affect Valuation

Stock Ticker

The Tuesday plenary luncheon at the 2012 BIO CEO & Investor Conference featured a panel of experts representing several perspectives on valuation. The session opened with Ben Bonifant, Senior Vice President & Practice Area Leader at Campbell Alliance, presenting results from their Corporate Value Study, which was followed by a discussion examining the key value drivers for emerging companies. Bonifant moderated the panel discussion that featured: Rachel K. King, Chief Executive Officer, GlycoMimetics, Inc. Michael Margolis, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Fireside Chat with Dr. Mikael Dolsten

Dolsten

Day two of the BIO CEO & Investor Conference kicked off with a Fireside Chat featuring Mikael Dolsten, MD, Phd, president, worldwide research & development from Pfizer, Inc and moderated by Mark Schoenebaum, senior biotechnology analyst with ISI Group. Speaking to a full room, Dr. Dolsten touched on Pfizer’s R&D priorities and their increased efforts to focus on investor capital return through a strong mixture of science, business and financial endeavors. In focusing on R&D, Pfizer has Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Sizing up the NBI in 2011

How did the Nasdaq Biotechnology Index (NBI) perform in 2011 relative to other sectors? Second place. Not so bad considering 2011 was the year of defense in the stock market. Like a page out of a textbook on defensive market plays, utilities edged out ahead with a +15% gain, followed by consumer staples with 11%. The NBI squeezed in between at 12%, just above the overall healthcare sector. Overall, the S&P500 was flat for the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Where’s the Deal?

2011-drug-deals-thumb

With only two weeks to go in 2011 it is looking like a five year low for deals. The chart below shows therapeutic deals dropping every year since 2007. We use the Windhover/Elsevier Strategic Transaction Database as our starting point for deal analytics. We analyze each deal to determine if the deal is for a drug asset, removing generic/OTC deals, manufacturing/service deals, device/diagnostics/tools deals, and tech transfer deals. What remains are deals for biotech company Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,